Organ Preservation Market Size, Share & Industry Analysis, By Product Type (Preservation Solutions & Media {Static Cold Storage (SCS) Solutions, Perfusion/Oxygenated Solutions, and Others}, Machine Perfusion Systems, Perfusion Consumables & Disposables, Cold-Chain Devices & Transport, and Monitoring Devices & Accessories), By Preservation Technique (Static Cold Storage (SCS), Hypothermic Machine Perfusion (HMP), Normothermic Machine Perfusion (NMP), Cryopreservation / Deep-freeze, and Others), By Organ Type, By End User, and Regional Forecast, 2025-2032

The global organ preservation market size was valued at USD 280.1 million in 2024 and is projected to grow from USD 323.8 million in 2025 to USD 624.6 million by 2032, exhibiting a CAGR of 9.8% during the forecast period. North America dominated the global market with a share of 36.38% in 2024.

Organ preservation refers to the coordinated clinical and logistical processes that ensure a donated organ remains viable from recovery to transplantation. The primary objective is to maintain functional integrity and minimize tissue damage caused by ischemia or reperfusion. Effective preservation techniques allow healthcare providers to safely extend storage durations and transport distances, ultimately improving transplant success rates and accessibility.

Furthermore, the market comprises several major players, with TransMedics, XVIVO, Terumo Corporation, Getinge AB, and Organ Recovery Systems at the forefront. Broad product portfolio with novel product launch, and robust geographic presence expansion have supported the dominance of these companies in the global market.

MARKET DYNAMICS

MARKET DRIVERS

Rapid Adoption and Innovation of Perfusion Machine to Propel Market Growth

The most prominent driver for the market is the increasing adoption and innovation of perfusion machines, and the regulatory approval of the novel machine in several developing countries is also anticipated to boost the demand for these products.

• For instance, in October 2024, Health Canada approved the OrganOx metra System for liver transplantation. The company plans to launch the system in Canada commercially in 2025.

Moreover, the increasing number of transplant procedures and rising awareness of organ transplantation in developing countries are anticipated to accelerate organ preservation market growth.

• According to the GODT/IRODaT 2023 data, there is a 9-10% increase in solid-organ transplants worldwide in 2023. Also, India has recorded a substantial increase in organ transplants in recent years. The National Organ and Tissue Transplant Organisation (NOTTO) reported ~18,378 transplants in 2023, a large jump versus a decade earlier and a new national high.

MARKET RESTRAINTS

High Cost of Capital Equipment and High Operating Cost of Machines to Restrict Market Expansion

The high cost associated with equipment and its operating costs is anticipated to restrain market growth during the forecast period.

• For example, a report published by The National Institute for Health and Care Excellence (NICE), the cost of the single-use OCS Heart Perfusion Set is about £30,000 (USD 40,000), and the approximate cost of the reusable OCS Heart console is £180,000 (USD 240,000).

Additionally, advanced cold chain transportation, logistics, and skilled professionals to handle and transport organs from one place to another are leading to a high operating and procedure cost.

• For example, according to articles published, it is estimated that Paragonix SherpaPak, an advanced organ transplant system, can cost between USD 9,000 and USD 17,000 per shipment/use.

MARKET OPPORTUNITIES

Emergence of Innovative Preservation Solutions to Create Lucrative Growth Opportunities

Preservation solutions are playing a vital role in preserving and transporting solid organs, and constant innovation and improvement in perfusates are creating lucrative growth opportunities in the market. Such as adding a stable oxygen carrier to existing solutions reduces dependence on blood, improves tissue oxygenation during cold storage/perfusion, and can extend tolerance to ischemia.

• For instance, HEMO2life (M101), an extracellular hemoglobin from a marine worm, is being used as an additive to static cold storage and machine perfusion solutions to supply oxygen and antioxidant activity during preservation. Clinical and preclinical work (including multicenter studies) shows improved graft function/lower delayed graft function when added to preservation fluids.

ORGAN PRESERVATION MARKET TRENDS

Shift toward Hypothermic and Normothermic Machine Perfusion is One of the Significant Market Trends

In recent years, healthcare providers or organ procurement organizations (OPOs) have gradually shifted their focus to hypothermic and normothermic machine perfusion from the static cold storage (SCS) preserving technique. Static cold storage (SCS) preserving techniques still dominate the market. Still, it is losing relative share as HMP/NMP adoption rises, as hypothermic and normothermic machine perfusion offers more viability and a high success rate of survival of organs.

• For example, a few research trials show machine perfusion most clearly improves early graft function, reduces specific complications such as delayed graft function (DGF) in kidneys and early allograft dysfunction (EAD) and ischemic biliary complications in livers, and increases usable organ rate.

MARKET CHALLENGES

Limited Donor Organ Availability to Hamper Market Growth

One of the significant factors challenging the market growth is limited donor organ availability, coupled with competition from emerging alternatives such as advances in artificial organs, xenotransplantation, and bioengineered tissues may partially reduce future demand for traditional preservation methods.

• For instance, according to Organdonor.gov, there are more than 100,000 people on the U.S. transplant waiting list, while the system performed 48,149 organ transplants in 2024, i.e., the total annual supply met only a fraction of current demand. As a result, dozens of patients die each day waiting for a suitable organ.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product Type

High Demand for Preservation Solutions & Media Contributed to Segmental Growth

On the basis of the segmentation of product type, the market is classified into preservation solutions & media, machine perfusion systems, perfusion consumables & disposables, cold-chain devices & transport, monitoring devices & accessories, and others. Preservation solutions & media are further classified into static cold storage (SCS) solutions, perfusion/oxygenated solutions, and others. Moreover, machine perfusion systems are further classified into hypothermic machine perfusion, normothermic machine perfusion, and others.

The preservation solutions & media segment accounted for the significant organ preservation market share in 2024. The growing demand for these products, owing to their wide usage in a broad range of solid organ transplantation applications, has resulted in the dominance of this segment in the market. Also, these products offer greater viability and success rate for transplantation, and have a large number of providers that operate in the market.

• For instance, TransMedics, XVIVO, Terumo Corporation, and Getinge AB are some of the major players in the market that offer a wide range of exonuclease II enzymes.

The perfusion consumables & disposables segment is expected to grow at a CAGR of 13.1% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Preservation Technique

Increasing Use of Static Cold Storage Led to Segmental Growth

In terms of preservation technique, the market is categorized into static cold storage (SCS), hypothermic machine perfusion (HMP), normothermic machine perfusion (NMP), cryopreservation/deep-freeze, and others.

The static cold storage (SCS) segment captured the largest share of the market in 2024. In 2025 the segment is anticipated to dominate with a 53.8% share. The static cold storage (SCS) technique plays an important role in organ preservation as it is a traditional method that is simple, inexpensive, and portable.

Normothermic machine perfusion (NMP) segment is expected to grow at a CAGR of 15.3% over the forecast period.

By Organ Type

High Kidney Transplant Volume Supplemented Segment Growth

Based on organ type, the market is segmented into kidney, liver, heart, lung, pancreas, and others.

The kidney segment held the dominating position in 2024. By organ type, the kidney segment held a share of 52.2% in 2024. Large kidney transplant procedures and an aging population with kidney failure are driving the segment growth.

• For instance, according to the National Kidney Foundation, Inc., 10% of the population worldwide is affected by chronic kidney disease (CKD), and millions die each year as they do not have access to affordable treatment.
• Similarly, according to the Centers for Disease Control and Prevention (CDC), more than 1 in 7 U.S. adults, about 35.5 million people, or 14% are estimated to have CKD. CKD is more common in people aged 65 years or older (34%) than in people aged 45-64 years (12%) or 18–44 years (6%).

The heart organ type segment is set to flourish with a growth rate of 13.4% growth across the forecast period.

By End User

Hospital’s Active Involvement in Organ Transplantations Propelled Segment Growth

Based on end user, the market is segmented into hospitals, organ procurement organizations (OPOs), academics and research institutes, and others.

In 2024, the global market was dominated by the hospital segment in terms of end user. Hospitals have been the fastest to adopt novel perfusion techniques, which increases cases for heart & lung is one of the key factors supporting the dominance of this segment. Furthermore, the segment is set to hold 78.0% share in 2025.

• For instance, according to the United Network for Organ Sharing (UNOS), 48,149 organ transplants were performed in the U.S. in 2024, and mostly these were performed in hospitals.

In addition, organ procurement organizations (OPOs) end users are projected to grow at a CAGR of 9.2% during the study period.

Organ Preservation Market Regional Outlook

By region, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2023 valuing at USD 98.5 million and also took the leading share in 2024, with USD 101.9 million. The factors fostering the dominance of the region include the presence of a large number of organ procurement organizations (OPOs), the highest early adoption of perfusion machines, favorable reimbursement in several centers, and the presence of well-established market players, among others. In 2025, the U.S. market is estimated to reach USD 112.8 million.

• For instance, in the U.S., there are 55 organ procurement organizations (OPOs) that are a formal channel for organ recovery and transport and do some purchasing and coordination among patients and healthcare providers.

Europe and Asia Pacific

Other regions, such as Europe and Asia Pacific, are anticipated to witness a notable growth in the coming years. During the forecast period, the European region is projected to record a growth rate of 7.8%, which is the third highest amongst all the regions, and touch a valuation of USD 70.1 million in 2025. This is primarily due to the rise in transplantation procedures in these regions, leading to high demand for organ preservation products. Backed by these factors, countries including the U.K. anticipate to record the valuation of USD 9.3 million, Germany to record USD 7.3 million, and France to record USD 11.7 million in 2025.

The market in Asia Pacific is estimated to reach USD 97.2 million in 2025 and secure the position of the second-largest region in the market. In the region, India and China are both estimated to reach USD 32.7 million and USD 31.9 million, respectively in 2025.

Latin America and Middle East & Africa

Over the forecast period, Latin America and Middle East & Africa regions would witness a moderate growth in this marketspace. The Latin America market in 2025 is set to record USD 27.3 million as its valuation. The rising incidence of organ failure and the rise in the number of organ transplantation procedures further drive usage in these regions. In the Middle East & Africa, GCC is set to attain the value of USD 9.8 million in 2025.

COMPETITIVE LANDSCAPE

Key Industry Players

Wide Range of Product Offerings coupled with Strong Distribution Network of Key Companies Supported their Leading Position

The global market shows a semi-consolidated structure with numerous small- to mid-size companies actively operating across the globe. These players are actively involved in product innovation, strategic partnerships, and geographic expansion.

TransMedics, XVIVO, Terumo Corporation, and Getinge AB  are some of the dominating players in the market. A comprehensive range of organ preservation products, global presence through a strong distribution network, and collaborations with research and academic institutes are a few characteristics of these players that support their dominance.

Apart from this, other prominent players in the market include Organ Recovery Systems, Bridge to Life Ltd., Vascular Perfusion Solutions, Inc., Preservation Solutions, Inc., and others. These companies are undertaking various strategic initiatives, such as investments in R&D and partnerships with hospitals to enhance their market presence.

LIST OF KEY ORGAN PRESERVATION COMPANIES PROFILED

• TransMedics (U.S.)
• XVIVO (Sweden)
• Terumo Corporation (Japan)
• Getinge AB (Sweden)
• Organ Recovery Systems (U.S.)
• Bridge to Life Ltd. (U.S.)
• Vascular Perfusion Solutions, Inc. (U.S.)
• Preservation Solutions, Inc. (U.S.)
• Waters Medical Systems (U.S.)
• Lifeline Scientific, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• September 2025: OrganOx Ltd., the organ technology company tackling the world's toughest transplant challenges, announced that its metra normothermic machine perfusion (NMP) device has received approval from the U.S. Food and Drug Administration (FDA) for operation during air transport.
• August 2025: TransMedics, a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), allowing the company to proceed with the initiation of its Next-Generation OCS ENHANCE Heart trial.
• January 2025: Cryoport, Inc., a global leader in supply chain solutions for the life sciences, unveiled its Cryoport Express Cryogenic HV3 Shipping System ("HV3"), the Company's newest product innovation in Cryoport's comprehensive portfolio of global end-to-end temperature-controlled supply chain offerings.
• September 2024: Getinge AB completed the previously announced acquisition of Paragonix Technologies, Inc., a leading U.S. company in organ transport products and services.
• January 2022: XVIVO was granted U.S. Food and Drug Administration (FDA) 510(k) clearance for its Kidney Assist Transport. This transportable organ perfusion system provides continuous oxygenated perfusion for up to 24 hours. The device has been shown to improve preservation compared to cold storage.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation